Ultragenyx Pharmaceutical (RARE)

• Market cap: $2.11B
• 1 day: 6.75%
• 5 days: -8.89%
• 1 month: -3.54%
• 3 months: -31.48%
• 6 months: -25.03%
• Year to date: -7.5%
• 1 year: -50.71%
• 5 years: -85.26%
• 10 years: -65.5%
• Sector: Healthcare
• Industry: Biotechnology

About: Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Employees: 1,294